News

Fintel reports that on May 16, 2023, Raymond James maintained coverage of uniQure N.V. (NASDAQ:QURE) with a Outperform recommendation.

Analyst Price Forecast Suggests 144.54% Upside

As of May 11, 2023, the average one-year price target for uniQure N.V. is 52.97. The forecasts range from a low of 24.24 to a high of $94.50. The average price target represents an increase of 144.54% from its latest reported closing price of 21.66.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for uniQure N.V. is 201MM, an increase of 82.44%. The projected annual non-GAAP EPS is -1.27.

What is the Fund Sentiment?

There are 305 funds or institutions reporting positions in uniQure N.V.. This is a decrease of 1 owner(s) or 0.33% in the last quarter. Average portfolio weight of all funds dedicated to QURE is 0.17%, a decrease of 13.12%. Total shares owned by institutions increased in the last three months by 2.56% to 44,160K shares.

The put/call ratio of QURE is 0.38, indicating a bullish outlook.

What are Other Shareholders Doing?

Nantahala Capital Management holds 3,070K shares representing 6.46% ownership of the company. In it's prior filing, the firm reported owning 2,700K shares, representing an increase of 12.05%. The firm increased its portfolio allocation in QURE by 19.43% over the last quarter.

IJR - iShares Core S&P Small-Cap ETF holds 3,067K shares representing 6.45% ownership of the company. In it's prior filing, the firm reported owning 3,007K shares, representing an increase of 1.95%. The firm increased its portfolio allocation in QURE by 12.12% over the last quarter.

PFM Health Sciences holds 2,110K shares representing 4.44% ownership of the company. In it's prior filing, the firm reported owning 2,302K shares, representing a decrease of 9.11%. The firm increased its portfolio allocation in QURE by 0.43% over the last quarter.

Orbimed Advisors holds 2,064K shares representing 4.34% ownership of the company. In it's prior filing, the firm reported owning 1,748K shares, representing an increase of 15.35%. The firm increased its portfolio allocation in QURE by 7.25% over the last quarter.

XBI - SPDR(R) S&P(R) Biotech ETF holds 1,907K shares representing 4.01% ownership of the company. In it's prior filing, the firm reported owning 2,299K shares, representing a decrease of 20.54%. The firm decreased its portfolio allocation in QURE by 14.68% over the last quarter.

uniQure N.V. Background Information
(This description is provided by the company.)

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.

Key filings for this company:

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.